Taylor James R
College of Pharmacy, University of Florida, Gainesville, 32610-0486, USA.
Pharmacotherapy. 2006 May;26(5):719-21. doi: 10.1592/phco.26.5.719.
53-year-old woman with a history of deep vein thrombosis and pulmonary embolism was receiving warfarin to prevent thromboembolic complications; her international normalized ratio (INR) had been stable for 1 month. Extended-release tolterodine 4 mg/day was then prescribed to manage overactive bladder. On her next anticoagulation clinic visit, the patient's INR had increased, although the dosage of warfarin had been reduced when the tolterodine had been prescribed. Due to the absence of other contributing factors and the temporal relationship between tolterodine and prolonged INR, the event was determined to be a probable drug interaction. When patients are prescribed tolterodine and warfarin concurrently, clinicians should monitor INR carefully, and a reduction in warfarin dosage may be required.
一名有深静脉血栓形成和肺栓塞病史的53岁女性正在接受华法林治疗以预防血栓栓塞并发症;她的国际标准化比值(INR)已经稳定了1个月。随后开具了4毫克/天的缓释托特罗定以治疗膀胱过度活动症。在她下次抗凝门诊就诊时,尽管在开具托特罗定处方时已减少了华法林的剂量,但患者的INR仍升高了。由于没有其他促成因素以及托特罗定与INR延长之间的时间关系,该事件被确定为可能的药物相互作用。当同时给患者开具托特罗定和华法林时,临床医生应仔细监测INR,可能需要减少华法林的剂量。